Research Projects (Dr. Manisha Ghate, Scientist G)
Name of the research study |
Role |
Year |
Clinical progression in HIV infected individuals (CPI) |
Co-Principal investigator |
2000-2005 |
RO1 study: Early HIV infection study |
Co-investigator |
2000-2005 |
HIV incidence and participant retention study (HPTN 034) |
Study Coordinator |
2002-2004 |
Women and AIDS study |
Co-investigator |
2002-2005 |
Pilot study to assess validity of HIV Dementia scale among HIV infected and uninfected individuals in Pune, India |
Principal investigator |
2005-2006 |
Feasibility study on HIV Dementia using a comprehensive battery in Pune, India |
Principal investigator |
2005-2006 |
Adolescent and Sexuality Study |
Co-investigator |
2005-2007 |
Development of Long term on progressor cohort |
Co-investigator |
2008-2016 |
NeuroAIDS in India |
Co-Principal Investigator |
2008-2013
|
Effect on HIV on cognitive aspects of children before and after ART initiation |
Principal investigator |
2012-2013 |
Characterization of cellular effector mechanism against HIV in cervicovaginal lavage among HIV infected women |
Co-investigator |
2014-2015 |
HIV-TB consortium: Support programme for HIV-TB coinfection |
Principal investigator |
2013-2016 |
Effectiveness of ART in free ART centres in Pune city |
Co-investigator |
2014-2015 |
Antibody Dependent Cellular toxicity: A new frontier in vaccine Development
|
Co-investigator |
2015-2016 |
Metabolic syndrome among People Living with HIV (PLWH) attending ART centre at Pune, India: a cross-sectional study |
Co-investigator |
2017-2018 |
Ocular manifestations among People Living with HIV (PLWH) attending ART centre at Pune, India: a cross-sectional study |
Principal investigator |
2018-2020 |
Knowledge, Attitude and practices towards COVID-19 among People Living with HIV (PLHIV) attending ART centre at Pune, India: a cross-sectional study |
Principal investigator |
2019-2020 |
Cohorts for HIV resistance and Progression in HIV infected children and adults |
Lead clinical investigator |
2018-ongoing |
Scaling up short course TB preventive regimen containing Isoniazid and Rifapentine given once-weekly for three months (3HP) among People Living with HIV/AIDS (PLHIV) and child contacts of sputum positive pulmonary TB patients in India: A demonstration project |
Principal investigator |
2021 –ongoing |
Detection of anti-SARS-COV-2 IgG antibodies, neutralizing antibodies and T cell immune response among HIV infected individuals attending ART Centre at ICMR-National AIDS Research Institute, Pune |
Principal investigator |
2020 –ongoing |
Study of genital Human papillomavirus infection in men: type-specific distribution, risk determinants and natural history among HIV-positive men and HIV-negative men |
Co-investigator |
2018-ongoing |
Project to introduce improved tests for monitoring of response to anti-tuberculosis treatment in HIV/TB co-infected patients |
Co-investigator |
2020-ongoing |
Determination of role of Osteopontin (OPN) and galectine-9 as biomarkers in active pulmonary TB |
Co-investigator |
2019-2020 |
A case control study to determine factors influencing epigenetic aging in HIV infection |
Co-investigator |
2020-ongoing |
COVAXINIMPLEMENTATIONPROTOCOL: Restricted Use in Emergency Situation in Clinical Trial Mode – Monitoring |
Nodal person |
2021 |
Clinical Trials:
Phase I safety and preliminary acceptability study of nonoxynol-9 pessary as a vaginal microbicide in low risk women |
Co-investigator |
1999-2001 |
A Phase I open-label study to assess the safety of repeated intravaginal doses of 0.5% PRO 2000/5 Gel (P) for 14 consecutive days between menses among sexually active HIV-uninfected women from Pune, India and to assess the acceptability of 0.5% PRO 2000/5 Gel (P) among sexually active HIV-uninfected women and men from Pune, India. (HPTN 047) |
Co-investigator |
2001-2003 |
A Randomized Trial to Evaluate the Effectiveness of Antiretroviral Therapy Plus HIV Primary Care versus HIV Primary Care Alone to Prevent the Sexual Transmission of HIV-1 in Serodiscordant Couples (HPTN 052 study) |
Co-investigator |
2006-2013 |
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings (PEARLS) (ACTG 5175) |
Co-investigator |
2005-2014 |
Clinical Trials Unit (CTU) |
CTU coordinator |
2007-2015
|
Operations Research:
Retention of antiretroviral naïve patients registered in HIV care in a program clinic in Pune, India |
Principal Investigator |
2013-2014 |
Effectiveness of first ART among HIV infected individuals attending ART centres in Pune city |
Co-investigator |
2014-2015 |
Assessment of feasibility of utilization of Early-Warning Indicators for monitoring of HIV Drug Resistance emergence for patients on first line ART in ART |
Principal Investigator |
2014-2015 |
Study on transfer outpatients in the ART centre |
Principal Investigator |
2017-2018 |
Cross sectional study on opted out patients in the ART centre |
Principal Investigator |
2018-2019 |
Ten years retention among HIV infected individuals in ART centre |
Principal Investigator |
2018-2019 |
Average time for development of virological failure requiring treatment switch tosecond line ART |
Principal Investigator |
2018-2019 |
Experience:
Dr. Manisha Ghate is a clinician-researcher and worked in various national and international research studies and clinical trials in the capacity of Principal investigator, Co-Principal Investigator, Coordinator and Co-Investigator. She is recipient of the Indo US Science and Technology Forum grant award on ‘NeuroAIDS in India: Present findings and future directions. She has provided clinical support to various institutional studies.
She is Nodal Officer of antiretroviral therapy center where around 3500 patients are accessing treatment, care and support at NARI and has led important operational research studies on effectiveness of antiretroviral therapy, retention of patients in treatment and early warning indicators and quality care indicators for HIV drug resistance in the national ART programme. The ART centre has been awarded as one of the four best centers in country under her leadership. She has contributed to National ART programme in terms of coordinating trainings for doctors.
She was Nodal officer at ICMR-NARI site for Maharashtra for COVAXIN implementation protocol: Restricted Use in Emergency Situation in Clinical Trial Mode – Monitoring. ICMR- NARI contacted around 5000 vaccine beneficiaries in February and March 2021 for data collection on adverse events after 1st and 2nd dose of Covaxin.
She has presented papers and abstracts in various national and international conferences and published 90 papers in journals, contributed to book chapter and reports. She is a recognized PhD guide, reviewer on ICMR Short Term Studentship (STS) programme, faculty for M. Sc Virology course and was on editorial board of national and international journals. She has made significant contributions in community awareness by taking research to the community through lectures, meetings and posters in local language.
Work Experience:
Grade/Post |
From |
To |
Institute |
Scientist G |
01/09/2020 |
Till date |
ICMR - National Institute Of Translation Virology And Aids Research (NITVAR) , Pune |
Scientist F |
01/09/2015 |
31/08/2020 |
ICMR - National Institute Of Translation Virology And Aids Research (NITVAR) , Pune |
Scientist E |
01/09/2010 |
31/08/2015 |
ICMR - National Institute Of Translation Virology And Aids Research (NITVAR) , Pune |
Scientist D |
07/08/2005 |
31/08/2010 |
ICMR - National Institute Of Translation Virology And Aids Research (NITVAR) , Pune |
Scientist C |
07/08/2000 |
06/08/2005 |
ICMR - National Institute Of Translation Virology And Aids Research (NITVAR) , Pune |
Scientist B |
07/08/1995 |
06/08/2000 |
ICMR - National Institute Of Translation Virology And Aids Research (NITVAR) , Pune |
Conferences/Trainings/Workshops Attended |
Trainings completed:
|
influenza-specific antibody-dependent cellular cytotoxicity-mediating antibodies
in HIV-infected Indian individuals. Infect Dis (Lond). 2018 Jan;50(1):35-43.
Effect of matrix metalloproteinase-21 (572C/T) polymorphism on HIV-associated neurocognitive disorder. APMIS. 2018 Apr;126(4):329-336.